What is CytoTronics?
CytoTronics is at the forefront of cell biology discovery, developing sophisticated Pixel systems that enable unprecedented visualization of live cell functions. Their technology facilitates multiplexed live-cell readouts, capturing extensive data on cell viability, morphology, and electrophysiology across diverse cell models. The company targets scientists in critical therapeutic areas, including vascular biology, stem cell differentiation, and oncology, empowering them with cloud-based software for rapid analysis of rich datasets to deepen the understanding of cell behavior.
How much funding has CytoTronics raised?
CytoTronics has raised a total of $22.8M across 2 funding rounds:
Angel/Seed
$9.3M
Angel/Seed
$13.5M
Angel/Seed (2022): $9.3M with participation from Anzu Partners and Milad Alucozai
Angel/Seed (2024): $13.5M led by BoxOne Ventures, Draper Associates, Anzu Partners, and LYFE Capital
Key Investors in CytoTronics
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, managing $1 billion in assets. They collaborate with a diverse team to support founders in bringing innovative solutions to market.
BoxOne Ventures
BoxOne Ventures is a privately held investment firm specializing in early-stage companies within impactful sectors such as biotechnology, food, clean energy, and longevity, investing their own capital to support entrepreneurs from inception to IPO.
Draper Associates
Draper Associates is a global venture capital firm with over 40 years of experience funding transformative companies across sectors like AI, blockchain, and biotech, focusing on backing innovative ideas and technologies that will shape the future.
What's next for CytoTronics?
The substantial enterprise-level funding and recent strategic investment signal a strong market validation for CytoTronics' innovative approach to cell biology research. This capital injection is expected to accelerate product development, expand market reach, and further enhance their cloud-based analytical capabilities. The company is well-positioned to solidify its leadership in providing advanced tools for cell biologists, driving new applications and insights in therapeutic research and development.
See full CytoTronics company page
